<![CDATA[CSL Vifor 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=41288>Fri, 01 May 2026 12:34:19 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Cancellation of remaining publicly held registered shares of Vifor Pharma AG]]>https://www.newswire.co.kr/newsRead.php?no=957910Wed, 14 Dec 2022 15:40:00 +0900<![CDATA[Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients]]>https://www.newswire.co.kr/newsRead.php?no=956606Mon, 28 Nov 2022 16:05:00 +0900<![CDATA[Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously]]>https://www.newswire.co.kr/newsRead.php?no=956508Fri, 25 Nov 2022 15:35:00 +0900<![CDATA[CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy]]>https://www.newswire.co.kr/newsRead.php?no=949946Tue, 23 Aug 2022 16:50:00 +0900<![CDATA[VFMCRP announces U.S. Court upholds validity of Velphoro® patent]]>https://www.newswire.co.kr/newsRead.php?no=949879Mon, 22 Aug 2022 16:30:00 +0900<![CDATA[Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022]]>https://www.newswire.co.kr/newsRead.php?no=949802Fri, 19 Aug 2022 14:50:00 +0900